Experimental Drug Shows Promise for Lupus Treatment
Late-stage clinical trial results indicate that Johnson & Johnson's nipocalimab effectively reduced disease activity in patients with systemic lupus erythematosus. This positive outcome suggests the drug could become a valuable new treatment option for individuals living with this chronic autoimmune condition.
Want more?
Open NewsSnap.ai for the full app experience, including audio, personalization, and more news tools.